Stem cell specialist ReNeuron (LON:RENE) has held an inaugural meeting of its newly-established Scientific Advisory Board, which comprises nine leading academics and industry executives.
The board’s role is to advise on topics related to ReNeuron’s areas of activity such as the future direction of cell therapy, academic, regulatory industrial and governmental links and relations with the media and the public.
The board is expected to meet twice a year.
Olav Hellebø, ReNeuron's chief executive, said: "We are honoured to have attracted such a prestigious group of leading, international academics and industry executives to our Scientific Advisory Board.
“The formal establishment of our SAB will enable the business to harness the collective knowledge of the SAB members across all aspects of drug development which will be invaluable as we drive our therapeutic programmes through the clinic and progress our exciting early stage work in exosomes."